Immunotherapy Treatment Shows Promise for Triple Negative Breast Cancer
The addition of neoadjuvant pembrolizumab to chemotherapy reduced triple negative breast cancer recurrence by more than a third, trial results suggested.
Source: medscape.com
Stay updated with breaking news from Prof Schmid. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The addition of neoadjuvant pembrolizumab to chemotherapy reduced triple negative breast cancer recurrence by more than a third, trial results suggested.
It was a clear, sunny, blue-sky day the day I learned I had breast cancer. The brutally unexpected so often seems to happen on such days.